Haleon stock edges lower as half-year 2026 earnings growth supports valuation
Published on 09/11/2026 at 21:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Haleon stock (ISIN GB00BMX86B70) closed at USD 9.22 on the New York Stock Exchange on September 10, 2026, down 0.16 percent from the previous close of USD 9.24 and about 9.7 percent below its level at the start of 2026, according to MarketBeat data cited by analyst overviews on September 10, 2026.
Half-year 2026 results show double-digit EPS growth
Fundamentally, Haleon’s most recent published half-year figures for H1 2026 underpin the current valuation by showing solid growth in revenue and earnings compared with the prior year period. According to Kalkine on September 11, 2026, Haleon reported revenue of GBP 5,602 million in the first half of 2026, up from H1 2025 and supported by strong demand in oral health brands such as Sensodyne.
In the same H1 2026 report, adjusted earnings per share increased by 12 percent versus H1 2025, highlighting the company’s ability to turn top-line growth into improving profitability despite cost pressures and marketing investment, as summarized by Kalkine on September 11, 2026.
Dividend and ex-dividend dates frame investor returns
Alongside earnings growth, Haleon’s capital-return profile is an important part of the investment case for retail investors looking at income. As Kalkine noted on September 11, 2026, Haleon shares on the London Stock Exchange went ex-dividend on August 13, 2026, while its American Depositary Shares went ex-dividend on August 14, 2026, marking the most recent dividend event for the stock.
For investors tracking yield, the MarketBeat overview for Haleon on September 10, 2026 indicated a dividend yield around 1.31 percent based on the latest annualized payout and the then-current share price, giving a modest income component alongside the company’s growth trajectory, according to MarketBeat on September 10, 2026.
Analyst view: moderate buy consensus despite year-to-date decline
The analyst community currently sees Haleon stock as a moderate buy, even after a year-to-date price decline. According to the Haleon page on MarketBeat dated September 10, 2026, Haleon has received a consensus rating described as Moderate Buy, based on a mix of strong buy, buy, hold and sell recommendations from the houses covering the stock.
The same MarketBeat summary reports that Haleon shares started 2026 at USD 10.12 and have since decreased by 9.7 percent to trade around USD 9.14 to USD 9.16, underscoring that the valuation has compressed despite the double-digit growth in adjusted EPS and stable dividend payments, as presented by MarketBeat on September 10, 2026.
Stock performance and current NYSE price context
In day-to-day trading, Haleon’s sponsored ADR on the NYSE under the symbol HLN shows relatively narrow intraday ranges, which is typical for large consumer health names. A corporate news wrap published by a financial portal on September 11, 2026 reported that Haleon plc (NYSE: HLN) closed at USD 9.22 on September 10, 2026 after trading between USD 9.18 and USD 9.25, with the small 0.16 percent decline leaving the shares near the midpoint of that intraday range and only USD 0.02 below an after-hours indication of USD 9.24 later that day.
Price snapshots compiled around September 10 and September 11, 2026 by sites such as MarketBeat and other stock portals show Haleon’s market capitalization near USD 40.31 billion based on a share price around USD 9.16 to USD 9.22 and roughly 4.4 billion shares outstanding, a level that places the company amongst the larger global consumer healthcare groups while still leaving room for potential re-rating if growth and margin trends remain intact, as reflected in data from MarketBeat on September 10, 2026.
Closing price and investor takeaway
As of the completed trading day on September 10, 2026, Haleon stock’s reference price on its primary US trading venue stood at USD 9.22 on the NYSE, with a modest 0.16 percent decline on the day and a roughly 9.7 percent drop since the start of 2026, while the latest half-year 2026 report showed revenue of GBP 5,602 million and a 12 percent rise in adjusted EPS compared with H1 2025.
Haleon stock profile
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: HLN
- Trading venue: NYSE (sponsored ADR)
- Price (as of September 10, 2026): 9.22 USD
- Market capitalization: 40.31 billion USD (as of September 10, 2026)
- Sector / Industry: Consumer healthcare / Pharmaceuticals
- Index membership: S&P 500
